Quantum Leap Healthcare Collaborative
search
Close
Close
I-SPY Trials - Meeting Abstracts
Close
Close
Copyright 2018, Quantum Leap Healthcare Collaborative
Agents & Results

Meeting Abstracts

The I-SPY Program is committed to open science, through timely publication and release of results, and ultimately data, from all arms of our trials.

I-SPY at 2019 SABCS

Please check again soon!

2022

Basu A, Umashankar S, Melisko M, et al.
Identification of symptoms that are associated with irAEs in the I-SPY clinical trial
.
2022 San Antonio Breast Cancer Symposium
, 
8-11 Dec
, 
2022
. In: 
;
 (
)
; Abstract No. 
GS5-04
.
abstract
doi link
poster (pdf)
slides (pdf)
Isaacs C, Nanda R, Chien J, et al.
Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
.
2022 San Antonio Breast Cancer Symposium
, 
8-11 Dec
, 
2022
. In: 
;
 (
)
; Abstract No. 
GS5-03
.
abstract
doi link
poster (pdf)
slides (pdf)
Zimmerman J, Carmona-Bozo J, Le NN, et al.
Diffusion-weighted magnetic resonance imaging for subtype-specific prediction of pathologic complete response in neoadjuvant chemotherapy
.
2022 San Antonio Breast Cancer Symposium
, 
8-11 Dec
, 
2022
. In: 
;
 (
)
; Abstract No. 
P6-01-33
.
abstract
doi link
poster (pdf)
slides (pdf)
Li W, Le NN, Onishi N, et al.
Association of MRI morphologic phenotype from unsupervised learning with breast cancer subtypes and treatment response
.
2022 San Antonio Breast Cancer Symposium
, 
8-11 Dec
, 
2022
. In: 
;
 (
)
; Abstract No. 
PD16-07
.
abstract
doi link
poster (pdf)
slides (pdf)
Onishi N, Jones EF, Carmona-Bozo J, et al.
Early MRI and PET biomarkers for hormone receptor-positive/HER2-negative early-stage breast cancer in the setting of neoadjuvant endocrine therapy and neoadjuvant chemotherapy in the I-SPY 2 TRIAL
.
2022 San Antonio Breast Cancer Symposium
, 
8-11 Dec
, 
2022
. In: 
;
 (
)
; Abstract No. 
PD16-06
.
abstract
doi link
poster (pdf)
slides (pdf)
Basu A, Umashankar S, Blevins K, et al.
The Association Between Symptom Severity and Physical Function among Participants in I-SPY2
.
2022 San Antonio Breast Cancer Symposium
, 
8-11 Dec
, 
2022
. In: 
;
 (
)
; Abstract No. 
P5-07-03
.
abstract
doi link
poster (pdf)
slides (pdf)
Magbanua MM, Rugo H, Brown-Swigart LA, et al.
Monitoring for response and recurrence in neoadjuvant-treated hormone receptor-positive HER2-negative breast cancer by personalized circulating tumor DNA testing
.
2022 San Antonio Breast Cancer Symposium
, 
8-11 Dec
, 
2022
. In: 
;
 (
)
; Abstract No. 
P5-05-05
.
abstract
doi link
poster (pdf)
slides (pdf)
Li W, Onishi N, Wolf DM, et al.
MRI models by response predictive subtype for predicting pathologic complete response
.
2022 San Antonio Breast Cancer Symposium
, 
8-11 Dec
, 
2022
. In: 
;
 (
)
; Abstract No. 
P4-02-10
.
abstract
doi link
poster (pdf)
slides (pdf)
Stringer-Reasor E, Shatsky RA, Chien J, et al
Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
.
2022 San Antonio Breast Cancer Symposium
, 
8-11 Dec
, 
2022
. In: 
;
 (
)
; Abstract No. 
PD11-01
.
abstract
doi link
poster (pdf)
slides (pdf)
Rosenbluth J, Bui TB, Warhadpande S, et al.
Characterization of residual disease after neoadjuvant selective estrogen receptor degrader (SERD) therapy using tumor organoids in the I-SPY Endocrine Optimization Protocol (EOP)
.
2022 San Antonio Breast Cancer Symposium
, 
8-11 Dec
, 
2022
. In: 
;
 (
)
; Abstract No. 
P3-09-01
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf DM, Yau C, Wulfkuhle J, et al.
Characterizing the HER2-/Immune-/DNA repair (DRD-) response predictive breast cancer subtype: the hunt for new protein targets in a high-needs population with low response to all I-SPY2 agents
.
2022 San Antonio Breast Cancer Symposium
, 
8-11 Dec
, 
2022
. In: 
;
 (
)
; Abstract No. 
PD5-04
.
abstract
doi link
poster (pdf)
slides (pdf)
Bui TBV, Wolf DM, Moore K,et al.
An Organoid Model System to Study Resistance Mechanisms, Predictive Biomarkers, and New Strategies to Overcome Therapeutic Resistance in Early-Stage Triple-Negative Breast Cancer
.
2022 San Antonio Breast Cancer Symposium
, 
8-11 Dec
, 
2022
. In: 
;
 (
)
; Abstract No. 
PD5-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Yee D, Shatsky RA, Yau C, et al.
Improved pathologic complete response rates for triple-negative breast cancer in the I-SPY2 Trial
.
2022 ASCO Annual Meeting
, 
3-7 Jun
, 
2022
. In: 
;
 (
)
; Abstract No. 
591
.
abstract
doi link
poster (pdf)
slides (pdf)
Thomas A, Clark AS, Yau C, et al.
Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial
.
2022 ASCO Annual Meeting
, 
3-7 Jun
, 
2022
. In: 
;
 (
)
; Abstract No. 
510
.
abstract
doi link
poster (pdf)
slides (pdf)
Huppert LA, Rugo HS, Pusztai L, et al.
Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial
.
2022 ASCO Annual Meeting
, 
3-7 Jun
, 
2022
. In: 
;
 (
)
; Abstract No. 
504
.
abstract
doi link
poster (pdf)
slides (pdf)
Cha J, Warner P, Hiatt R, et al.
Distribution of breast cancer molecular subtypes within receptor classifications: Lessons from the I-SPY2 Trial and FLEX Registry
.
2022 ASCO Annual Meeting
, 
3-7 Jun
, 
2022
. In: 
;
 (
)
; Abstract No. 
592
.
abstract
doi link
poster (pdf)
slides (pdf)
Mittempergher L, Kuilman MM, Barcaru A, et al.
The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2
.
2022 ASCO Annual Meeting
, 
3-7 Jun
, 
2022
. In: 
;
 (
)
; Abstract No. 
514
.
abstract
doi link
poster (pdf)
slides (pdf)

2021

Kyalwazi B, Yau C, Olopade O, et al.
Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial
.
2021 San Antonio Breast Cancer Symposium
, 
7-10 Dec
, 
2021
. In: 
;
 (
)
; Abstract No. 
GS4-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Northrop A, Christofferson A, Melisko M, et al.
Improving patient-reported outcome data capture for clinical research: ePRO in ISPY 2, a phase 2 breast cancer study
.
2021 San Antonio Breast Cancer Symposium
, 
7-10 Dec
, 
2021
. In: 
;
 (
)
; Abstract No. 
P4-12-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Goodarzi H, Navickas A, Wang J, et al.
Tumor-released circulating orphan non-coding RNAs reflect treatment response and survival in breast cancer
.
2021 San Antonio Breast Cancer Symposium
, 
7-10 Dec
, 
2021
. In: 
;
 (
)
; Abstract No. 
PD9-04
.
abstract
doi link
poster (pdf)
slides (pdf)
Christofferson A, Price E, Mukhtar RA, et al.
Single-institution retrospective analysis of lymph node (LN) change on breast MRI in patients with high risk early-stage breast cancer receiving neoadjuvant chemotherapy with and without immunotherapy on the ISPY-2 TRIAL
.
2021 San Antonio Breast Cancer Symposium
, 
7-10 Dec
, 
2021
. In: 
;
 (
)
; Abstract No. 
P3-03-07
.
abstract
doi link
poster (pdf)
slides (pdf)
Bareng TJ, Gibbs JE, Onishi N, et al.
Challenges of achieving high image quality on breast MRI for quantitative measurements in the I-SPY 2 TRIAL
.
2021 San Antonion Breast Cancer Symposium
, 
7-10 Dec
, 
2021
. In: 
;
 (
)
; Abstract No. 
P3-03-04
.
abstract
doi link
poster (pdf)
slides (pdf)
Li W, Le NN, Onishi N, et al.
Diffusion-weighted MRI for prediction of pathologic complete response in HER2- breast cancer treated with pembrolizumab plus neoadjuvant chemotherapy
.
2021 San Antonio Breast Cancer Symposium
, 
7-10 Dec
, 
2021
. In: 
;
 (
)
; Abstract No. 
P3-03-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Onishi N, Gibbs JE, Li W, et al.
Functional tumor volume at 3 and 6-week MRI as an indicator of patients with inferior outcome after neoadjuvant chemotherapy
.
2021 San Antonio Breast Cancer Symposium
, 
7-10 Dec
, 
2021
. In: 
;
 (
)
; Abstract No. 
.
abstract
doi link
poster (pdf)
slides (pdf)
Jones EF, Hathi DK, Konovalova N, et al.
Initial experience of FES-dedicated breast PET imaging of early-stage ER+ invasive lobular carcinoma
.
2021 San Antonio Breast Cancer Symposium
, 
7-10 Dec
, 
2021
. In: 
;
 (
)
; Abstract No. 
P3-02-01
.
abstract
doi link
poster (pdf)
slides (pdf)
Jones EF, Hathi DK, Molina-Vega J, et al.
FES-dedicated breast PET uptake in early-stage ER+ breast cancers
.
2021 San Antonio Breast Cancer Symposium
, 
7-10 Dec
, 
2021
. In: 
;
 (
)
; Abstract No. 
P3-02-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Chien AJ, Kalinsky KM, Molina-Vega J, et al.
I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer
.
2021 San Antonio Breast Cancer Symposium
, 
7-10 Dec
, 
2021
. In: 
;
 (
)
; Abstract No. 
OT1-10-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Potter DA, Roesch E, Yau C, et al.
Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL
.
2021 San Antonio Breast Cancer Symposium
, 
7-10 Dec
, 
2021
. In: 
;
 (
)
; Abstract No. 
PD8-07
.
abstract
doi link
poster (pdf)
slides (pdf)
Sayaman RW, Wolf DM, Yau C, et al.
Elucidating the biology of circulating tumor DNA (ctDNA) shedding across receptor subtypes in high-risk early-stage breast cancer
.
2021 San Antonio Breast Cancer Symposium
, 
7-10 Dec
, 
2021
. In: 
;
 (
)
; Abstract No. 
P2-01-03
.
abstract
doi link
poster (pdf)
slides (pdf)
Chien AJ, Soliman HH, Ewing CA, et al.
Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 tria
.
2021 ASCO Annyal Meeting
, 
4-8 Jun
, 
2021
. In: 
;
 (
)
; Abstract No. 
508
.
abstract
doi link
poster (pdf)
slides (pdf)
Marczyk M, Mrukwa A, Yau C, et al.
Treatment Efficacy Score (TES), a continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between trial arms in the I-SPY 2 trial
.
2021 ASCO Annual Meeting
, 
4-8 Jun
, 
2021
. In: 
;
 (
)
; Abstract No. 
587
.
abstract
doi link
poster (pdf)
slides (pdf)
Soliman H, Wolf D, Chien J, et al.
Chemokine12 (CK12) tertiary lymphoid gene expression signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY 2 TRIAL - pembrolizumab with and without SD101, and durvalumab combined with olaparib - and in 9 other arms of the trial including platinum- based and dual-anti-HER2 therapies
.
2021 San Antonio Breast Cancer Symposium
, 
7-10 Dec
, 
2021
. In: 
;
 (
)
; Abstract No. 
PD10-07
.
abstract
doi link
poster (pdf)
slides (pdf)

2020

Yee D, Haluska P, Wolf DM, et al.
Biomarker analysis of paclitaxel, ganitumab, and metformin (PGM) therapy in the I-SPY2 neoadjuvant clinical trial
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
PS4-08
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf DM, Yau C, Brown-Swigart L, et al.
Biomarkers predicting response to durvalumab combined with olaparib in the neoadjuvant I-SPY 2 TRIAL for high-risk breast cancer
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
PD14-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Shad S, van der Noordaa M, Osdoit M, et al.
Site of recurrence after neoadjuvant therapy: a multi-center pooled analysis
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
PD13-02
.
abstract
doi link
poster (pdf)
slides (pdf)
van der Noordaa MEM, Yau C, Shad S, et al.
Assessing prognosis after neoadjuvant therapy: A comparison between anatomic ypAJCC staging, Residual Cancer Burden Class and Neo-Bioscore
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
GS4-07
.
abstract
doi link
poster (pdf)
slides (pdf)
Li W, Newitt DC, Gibbs J, et al.
Subtype-specific MRI models to guide selection of candidates for de-escalation of neoadjuvant therapy
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
PD6=-5
.
abstract
doi link
poster (pdf)
slides (pdf)
Magbanua MJM, Wolf D, Renner D, et al.
Personalized circulating tumor DNA (ctDNA) as predictive biomarker in high-risk early stage breast cancer (EBC) treated with neoadjuvant chemotherapy (NAC) with or without pembrolizumab (P)
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
PD9-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Wulfkuhle J, Wolf D, Yau C, et al.
Identification of biomarkers associated with therapeutic resistance: quantitative protein/phosphoprotein analysis of ~750 patients across 8 arms of the neoadjuvant I-SPY 2 TRIAL for high-risk early stage breast cancer
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
PD9-04
.
abstract
doi link
poster (pdf)
slides (pdf)
Yu K, Basu A, Yau C, et al.
Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatment arms and molecular subtypes
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
PS11-04
.
abstract
doi link
poster (pdf)
slides (pdf)
Gibbs J, Newitt DC, Watkins M, et al.
Operational standardization and quality assurance yield high acceptance rate for breast MRI in the I-SPY 2 TRIAL
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
PS11-08
.
abstract
doi link
poster (pdf)
slides (pdf)
Beckwith H, Schwab R, Yau C, et al.
Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
PD1-10
.
abstract
doi link
poster (pdf)
slides (pdf)
Wang H, Yee D, Potter D, et al.
Impact of Body Mass Index on Pathological Complete Response after Neoadjuvant Chemotherapy: Results from the I-SPY 2 trial
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
PS6-05
.
abstract
doi link
poster (pdf)
slides (pdf)
Onishi N, Li W, Venters SJ, et al.
Radiologic review to refine selection of candidates for de-escalation of neoadjuvant therapy after mid-treatment biopsy
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
PS3-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Bareng TJ, Gibbs J, Li W, et al.
Assessment of clip locations on breast MRI during NAC to guide tumor bed biopsy at mid-treatment
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
PS3-14
.
abstract
doi link
poster (pdf)
slides (pdf)
Hathi DK, Jones EF, Li W, et al.
Relationship of dedicated breast PET and MRI features in breast cancer patients receiving neoadjuvant chemotherapy
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
PS13-50
.
abstract
doi link
poster (pdf)
slides (pdf)
Venters SJ, Li W, Wolf DM, et al.
Serial MRI and pathology combined to select candidates for therapy de-escalation in the I-SPY 2 TRIAL
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
PS4-10
.
abstract
doi link
poster (pdf)
slides (pdf)
Carter JM, Klein ME, Venters SJ, et al.
Pathologic features of the inter-regimen biopsy predict response to neoadjuvant therapy in the I-SPY2 trial
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
PS4-09
.
abstract
doi link
poster (pdf)
slides (pdf)
Magbanua MJM, van 't Veer L, Clark A, et al.
Outcomes associated with disseminated tumor cells at surgery after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT Study
.
2020 San Antonio Breast Cancer Symposium
, 
Dec 8-11
, 
2020
. In: 
;
 (
)
; Abstract No. 
PS2-07
.
abstract
doi link
poster (pdf)
slides (pdf)
Pusztai L, Han HS, Yau C, et al.
Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
.
2020 AACR
, 
June 20-24
, 
2020
. In: 
;
 (
)
; Abstract No. 
CT011
.
abstract
doi link
poster (pdf)
slides (pdf)

2019

Pohlmann PR, Yau C, DeMichele A, et al.
Amsterdam 70-gene profile (MammaPrint) Low Risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
P6-10-06
.
abstract
doi link
poster (pdf)
slides (pdf)
Li W, Onishi N, Newitt DC, et al.
The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
P6-02-01
.
abstract
doi link
poster (pdf)
slides (pdf)
Venters SJ, Wolf DM, Brown-Swigart L, et al.
Assessing biomarkers to inform treatment de-escalation: mid-treatment biopsy cellularity predicts pCR in the I-SPY 2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
P6-10-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Magbanua MM, Brown-Swigart L, Hirst G, et al.
Personalized monitoring of circulating tumor DNA during neoadjuvant therapy in highrisk early stage breast cancer reflects response and risk of metastatic recurrence
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
P5-01-04
.
abstract
doi link
poster (pdf)
slides (pdf)
Ghersin H, Chattopadhyay A, Blaes A, et al.
Introducing an electronic platform to collect patient reported outcomes in the I-SPY 2 TRIAL, a neoadjuvant clinical trial
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
OT3-19-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Yau C, van der Noordaa M, Wei J, et al.
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: a multi-center pooled analysis
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
GS5-01
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf DM, Yau C, Wulfkuhle J, et al.
HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
P4-10-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Sayaman RW, Wolf DM, Yau C, et al.
Application of Machine Learning to elucidate the biology predicting response in the I‑SPY 2 neoadjuvant breast cancer trial
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
P1-21-08
.
abstract
doi link
poster (pdf)
slides (pdf)
Onishi N, Li W, Newitt DC, et al.
Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
PD9-05
.
abstract
doi link
poster (pdf)
slides (pdf)
Li W, Onishi N, Newitt DC, et al.
Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
PD9-04
.
abstract
doi link
poster (pdf)
slides (pdf)
Arasu V, Kim P, Li W, et al.
Additive benefit of MRI background parenchymal enhancement (BPE) to an MRI tumor volume model for predicting pathologic complete response (pCR) to neoadjuvant treatment in I-SPY2
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
PD9-06
.
abstract
doi link
poster (pdf)
slides (pdf)
Osdoit M, Yau C, Symmans WF, et al.
The impact of residual ductal carcinoma in situ on breast cancer recurrence in the neoadjuvant I-SPY2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
P3-08-16
.
abstract
doi link
poster (pdf)
slides (pdf)
Helsten TL, Lo SS, Yau C, et al.
Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
P3-11-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Liu MC, Robinson PA, Yau C, et al.
Evaluation of a pembrolizumab-8 cycle neoadjuvant regimen without AC for high-risk early-stage HER2-negative breast cancer: Results from the I-SPY 2 TRIAL
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
P3-09-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Basu A, Philip EJ, Dewitt B, et al.
The Clinical Benefit Index: A Pilot Study Integrating Treatment Efficacy and Quality of Life in Oncology Clinical Trials
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
P2-12-06
.
abstract
doi link
poster (pdf)
slides (pdf)
Yau C, Symmans W, Pusztai L, et al.
Site of recurrence after neoadjuvant therapy: clues to biology and impact on endpoints
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
P2-20-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Du L, Yau C, Brown-Swigart L, et al.
Prognostic contribution of predicted sensitivity to endocrine therapy (SET) prior to neoadjuvant chemotherapy for stage II-III hormone receptor-positive and HER2- negative (HR+/HER2-) breast cancer
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
;
 (
)
; Abstract No. 
P2-11-04
.
abstract
doi link
poster (pdf)
slides (pdf)
Campbell MJ, Yau C, Bolen J, et al.
Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL
.
AACR Annual Meeting
, 
Mar 29 - APr 3
, 
2019
. In: 
Cancer Res
2019
;
79
 (
13 Suppl
)
; Abstract No. 
CT003
.
abstract
doi link
poster (pdf)
slides (pdf)
Li W, Newitt DC, Wilmes LJ, et al
Combination of MRI quantitative measures improves prediction of residual disease following neoadjuvant chemotherapy (NAC) for breast cancer in the I-SPY 2 TRIAL
.
ISMRM 27th Annual Meeting
, 
May 11-16
, 
2019
. In: 
;
 (
)
; Abstract No. 
0278
.
abstract
doi link
poster (pdf)
slides (pdf)
Wulfkuhle JD, Yau C, Wolf D, et al.
Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial
.
2019 ASCO Annual Meeting
, 
May 30 - June 4
, 
2019
. In: 
J Clin Oncol
2019
;
37
 (
15
)
; Abstract No. 
2631
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf DM, Yau C, Wulfkuhle J, et al.
Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial
.
AACR Annual Meeting 2019
, 
Mar 29 - Apr 3
, 
2019
. In: 
Cancer Res
2019
;
79
 (
13 Suppl
)
; Abstract No. 
2679
.
abstract
doi link
poster (pdf)
slides (pdf)
Yau C, van der Noordaa M, Wei J, et al
Abstract GS5-01: Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis
.
2019 San Antonio Breast Cancer Symposium
, 
December 10-14
, 
2019
. In: 
Cancer Research
2020
;
80
 (
4_Supplement
)
; Abstract No. 
GS5-01
.
abstract
doi link
poster (pdf)
slides (pdf)

2018

Hyland C, Varghese F, Yau C, et al.
The use of 18F-FDG PET/CT as an initial staging procedure for stage II-III breast cancer reduces false positives, costs, and time to treatment: a multicenter value analysis in the I-SPY2 trial
.
2018 San Antonio Breast Cancer Symposium
, 
December 4-8
, 
2018
. In: 
;
 (
)
; Abstract No. 
P5-15-01
.
abstract
doi link
poster (pdf)
slides (pdf)
Zhu Z, Yau C, van ’t Veer L, et al.
Molecular subtypes of invasive lobular breast cancer in the I-SPY2 Trial
.
2018 San Antonio Breast Cancer Symposium
, 
December 4-8
, 
2018
. In: 
;
 (
)
; Abstract No. 
PD7-06
.
abstract
doi link
poster (pdf)
slides (pdf)
Yau C, Wolf D, Campbell M, et al.
Expression-based immune signatures as predictors of neoadjuvant targeted-/chemo-therapy response: Experience from the I-SPY 2 TRIAL of ~1000 patients across 10 therapies
.
2018 San Antonio Breast Cancer Symposium
, 
December 4-8
, 
2018
. In: 
;
 (
)
; Abstract No. 
P3-10-06
.
abstract
doi link
poster (pdf)
slides (pdf)
Yau C, Brown-Swigart L, Asare S, et al/
LIV-1 Expression in Primary Breast Cancers in the I-SPY 2 TRIAL
.
2018 San Antonio Breast Cancer Symposium
, 
December 4-8
, 
2018
. In: 
;
 (
)
; Abstract No. 
P3-10-14
.
abstract
doi link
poster (pdf)
slides (pdf)
Li W, Newitt DC, Yun BL, et al.
MRI detection of residual disease following neoadjuvant chemotherapy (NAC) in the I-SPY 2 TRIAL
.
2018 San Antonio Breast Cancer Symposium
, 
December 4-8
, 
2018
. In: 
;
 (
)
; Abstract No. 
PD4-03
.
abstract
doi link
poster (pdf)
slides (pdf)
Hylton NM, Symmans WF, Yau C, et al.
Refining neoadjuvant predictors of three year distant metastasis free survival: integrating volume change as measured by MRI with residual cancer burden
.
2018 San Antonio Breast Cancer Symposium
, 
December 4-8
, 
2018
. In: 
;
 (
)
; Abstract No. 
P2-07-03
.
abstract
doi link
poster (pdf)
slides (pdf)
van der Noordaa MEM, Esserman L, Yau C, et al
Role of breast MRI in predicting pathologically negative nodes after neoadjuvant chemotherapy in cN0 patients in the I-SPY 2 trial
.
2018 San Antonio Breast Cancer Symposium
, 
December 4-9
, 
2018
. In: 
;
 (
)
; Abstract No. 
PD4-04
.
abstract
doi link
poster (pdf)
slides (pdf)
Silverstein J, Suleiman L, Yau C, et al.
The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL
.
2018 San Antonio Breast Cancer Symposium
, 
December 4-8
, 
2018
. In: 
;
 (
)
; Abstract No. 
P2-14-01
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf DM, Yau C, Wulfkhule J, et al.
Identifying breast cancer molecular phenotypes to predict response in a modern treatment landscape: lessons from ~1000 patients across 10 arms of the I-SPY 2 TRIAL
.
2018 San Antonio Breast Cancer Symposium
, 
December 4-8
, 
2018
. In: 
;
 (
)
; Abstract No. 
P3-10-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Magbanua M, Brown-Swigart L, Hirst G, et al
Personalized serial circulating tumor DNA (ctDNA) analysis in high-risk early stage breast cancer patients to monitor and predict response to neoadjuvant therapy and outcome in the I-SPY 2 TRIAL
.
2018 San Antonio Breast Cancer Symposium
, 
Dec 4-8
, 
2018
. In: 
;
 (
)
; Abstract No. 
PD2-01
.
abstract
doi link
poster (pdf)
slides (pdf)
van 't Veer L, Wolf D, Yau C, et al.
MammaPrint High1/High2 risk class as a pre-specified biomarker of response to nine different targeted agents plus standard neoadjuvant therapy for ~ 1000 breast cancer patients in the I-SPY 2 TRIAL
.
30th EORTC-NCI-AACR Symposium
, 
November 13-16
, 
2018
. In: 
;
 (
)
; Abstract No. 
.
abstract
doi link
poster (pdf)
slides (pdf)
Gallagher RI, Wulfkuhle JD, Yau C, et al
Association of activation levels of TIE2 with response to the angiogenesis inhibitor trebananib in HER2+ patients in the I-SPY 2 trial
.
2018 American Society of Cancer Oncology Annual Meeting
, 
June 1-5
, 
2018
. In: 
J Clin Oncol
2018
;
36
 (
suppl
)
; Abstract No. 
12103
.
abstract
doi link
poster (pdf)
slides (pdf)
Wulfkuhle JD, Wolf DM, Yau C, et al
Phosphorylation of AKT kinase substrates to predict response to the AKT inhibitor MK2206 in the I-SPY 2 trial in both HER2- and HER2+ patients
.
2018 American Society of Cancer Oncology Annual Meeting
, 
June 1-5
, 
2018
. In: 
J Clin Oncol
2018
;
36
 (
suppl
)
; Abstract No. 
12099
.
abstract
doi link
poster (pdf)
slides (pdf)
Fraser Symmans W, Yau C, Chen Y, et al
Residual cancer burden (RCB) as prognostic in the I-SPY 2 TRIAL
.
2018 American Society of Cancer Oncology Annual Meeting
, 
June 1-5
, 
2018
. In: 
J Clin Oncol
2018
;
36 suppl
 (
)
; Abstract No. 
520
.
abstract
doi link
poster (pdf)
slides (pdf)
William Fraser Symmans, Christina Yau, Yunn-Yi Chen, et al
Advances in Precision Medicine in Triple-Negative Breast Cancer: Residual cancer burden (RCB) as prognostic in the I-SPY 2 TRIAL Poster Presentation
.
2018 American Society of Cancer Oncology Annual Meeting
, 
June 1-5
, 
2018
. In: 
J Clin Oncol
2018
;
36
 (
suppl
)
; Abstract No. 
520
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf DM, Yau C, Brown-Swigart L, et al
Evaluation of ANG/TIE/hypoxia pathway genes and signatures as predictors of response to trebananib (AMG 86) in the neoadjuvant I-SPY 2 TRIAL for Stage II-III high-risk breast cancer
.
2018 AACR Annual Meeting
, 
April 14-18
, 
2018
. In: 
Cancer Res
2018
;
78
 (
13 Suppl
)
; Abstract No. 
2611
.
abstract
doi link
poster (pdf)
slides (pdf)
Lee PRE, Zhu Z, Wolf D, et al
BluePrint Luminal subtype predicts non-response to HER2-targeted therapies in HR+/HER2+ I-SPY 2 breast cancer patients
.
2018 AACR Annual Meeting
, 
April 14-18
, 
2018
. In: 
Cancer Res
2018
;
78
 (
13 Suppl
)
; Abstract No. 
2612
.
abstract
doi link
poster (pdf)
slides (pdf)

2017

Campbell M, Yau C, Borowsky A, et al.
Analysis of immune infiltrates (assessed via multiplex fluorescence immunohistochemistry) and immune gene expression signatures as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 trial
.
2017 San Antonio Breast Cancer Symposium
, 
Dec 5-9
, 
2017
. 
In: 
Cancer Res
2018
;
78
 (
4 Suppl
)
; Abstract No. 
PD6-08
.
abstract
doi link
poster (pdf)
slides (pdf)
Yee D, DeMichele A, Isaacs C, et al.
Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL
.
2017 San Antonio Breast Cancer Symposium
, 
Dec 5-9
, 
2017
. 
In: 
Cancer Res
2018
;
78
 (
4 Suppl
)
; Abstract No. 
GS3-08
.
abstract
doi link
poster (pdf)
slides (pdf)
Pradhan SM, Carey L, Edmiston S, et al.
P53 mutation and differential response to neoadjuvant chemotherapy in women with locally advanced breast cancer: Results from the I-SPY trial (CALGB 150007/1500012 and ACRIN 6657)
.
2017 American Society of Clinical Oncology Annual Meeting
, 
June 2-6
, 
2017
. 
In: 
J Clin Oncol
2009
;
27
 (
15 Suppl.
)
; Abstract No. 
11099
.
abstract
doi link
poster (pdf)
slides (pdf)
Nanda R, Liu MC, Yau C, et al.
Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2
.
2017 American Society of Clinical Oncology Annual Meeting
, 
June 2-6
, 
2017
. 
In: 
J Clin Oncol
2017
;
35
 (
15 Suppl.
)
; Abstract No. 
506
.
abstract
doi link
poster (pdf)
slides (pdf)
Partridge SC, Zhang Z, Newitt DC, et al.
ACRIN 6698 trial: Quantitative diffusion-weighted MRI to predict pathologic response in neoadjuvant chemotherapy treatment of breast cancer
.
2017 American Society of Clinical Oncology Annual Meeting
, 
June 2-6
, 
2017
. 
In: 
J Clin Oncol
2017
;
35
 (
15 Suppl.
)
; Abstract No. 
11520
.
abstract
doi link
poster (pdf)
slides (pdf)
Li W, Wilmes LJ, Newitt DC, et al.
Diffusion-weighted MRI improves imaging prediction of response in the I-SPY 2 trial
.
2017 San Antonio Breast Cancer Symposium
, 
December 5-9
, 
2017
. 
In: 
Cancer Res
2018
;
78
 (
4 Suppl.
)
; Abstract No. 
P2-09-23
.
abstract
doi link
poster (pdf)
slides (pdf)
Vidula N, Yau C, Rugo HS, et al.
Trop2 gene expression (Trop2e) in primary breast cancer (BC): Correlations with clinical and tumor characteristics.
.
2017 American Society of Cancer Oncology Annual Meeting
, 
June 2-6
, 
2017
. 
In: 
J Clin Oncol
2017
;
35
 (
15 Suppl.
)
; Abstract No. 
1075
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf D, Yau C, Brown-Swigart L, et al.
Analysis of biomarkers for response and resistance to the AKT inhibitor MK-2206 in the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer
.
2017 San Antonio Breast Cancer Symposium
, 
December 5-9
, 
2017
. 
In: 
Cancer Res
2018
;
78
 (
4 Suppl.
)
; Abstract No. 
P2-09-08
.
abstract
doi link
poster (pdf)
slides (pdf)
Yau C, Wolf D, Brown-Swigart L, et al.
Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer
.
2017 San Antonio Breast Cancer Symposium
, 
December 5-9
, 
2017
. 
In: 
Cancer Res
2018
;
78
 (
4 Suppl.
)
; Abstract No. 
PD6-14
.
abstract
doi link
poster (pdf)
slides (pdf)

2016

Vidula N, Yau C, Wolf DM, et al.
Androgen receptor (AR) expression in primary breast cancer (BC): Correlations with clinical characteristics and outcomes
.
2016 American Society of Clinical Oncology Annual Meeting
, 
June 3-7
, 
2016
. 
In: 
J Clin Oncol
2016
;
34
 (
15 Suppl.
)
, Abstract No. 
1072
.
abstract
doi link
poster (pdf)
slides (pdf)
DeMichele AM, Moulder S, Buxton M, et al.
Efficacy of T-DM1 + pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
.
AACR 107th Annual Meeting 2016
, 
April 16-20
, 
2016
. 
In: 
Cancer Res
2016
;
76
 (
14 Suppl.
)
, Abstract No. 
CT042
.
abstract
doi link
poster (pdf)
slides (pdf)
Buxton M, DeMichele AM, Chia S, et al.
Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
.
AACR 107th Annual Meeting 2016
, 
April 16-20
, 
2016
. 
In: 
Cancer Res
2016
;
76
 (
14 Suppl.
)
, Abstract No. 
CT106
.
abstract
doi link
poster (pdf)
slides (pdf)
Li W, Arasu V, Jones EF, et al.
Effect of MR imaging contrast kinetic thresholds for prediction of neoadjuvant chemotherapy response in breast cancer subtypes – Results from ACRIN 6657 / I-SPY 1 trial
.
2016 San Antonio Breast Cancer Symposium
, 
December 6-10
, 
2016
. 
In: 
Cancer Res
2016
;
77
 (
4 Suppl.
)
, Abstract No. 
PD3-05
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf DM, Yau C, Brown-Swigart L, et al.
Gene and pathway differences between MammaPrint High1/High2 risk classes: results from the I-SPY 2 TRIAL in breast cancer
.
AACR 107th Annual Meeting 2016
, 
April 16-20
, 
2016
. 
In: 
Cancer Res
2016
;
76
 (
14 Suppl.
)
, Abstract No. 
859
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf DM, Yau C, Sanil A, et al.
Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL
.
AACR 107th Annual Meeting 2016
, 
April 16-20
, 
2016
. 
In: 
Cancer Res
2016
;
76
 (
14 Suppl.
)
, Abstract No. 
858
.
abstract
doi link
poster (pdf)
slides (pdf)
Yee D, Paoloni M, Van't Veer L, et al.
The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
.
2016 San Antonio Breast Cancer Symposium
, 
December 6-10
, 
2016
. 
In: 
Cancer Res
2016
;
77
 (
4 Suppl.
)
, Abstract No. 
P6-11-04
.
abstract
doi link
poster (pdf)
slides (pdf)
Shah M, Jensen R, Yau C, et al.
Trajectory of patient (Pt) reported physical function (PF) during and after neoadjuvant chemotherapy in the I-SPY 2 trial
.
2016 San Antonio Breast Cancer Symposium
, 
December 6-10
, 
2016
. 
In: 
Cancer Res
2017
;
77
 (
4 Suppl.
)
, Abstract No. 
P5-11-18
.
abstract
doi link
poster (pdf)
slides (pdf)
Paoloni M, Lyandres J, Buxton MB, et al.
A longitudinal look at toxicity management within a platform trial: Lessons from the I-SPY 2 TRIAL
.
2016 San Antonio Breast Cancer Symposium
, 
December 6-10
, 
2016
. 
In: 
Cancer Res
2016
;
77
 (
4 Suppl.
)
, Abstract No. 
P2-11-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Forero A, Yee D, Buxton MB, et al.
Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
.
2016 San Antonio Breast Cancer Symposium
, 
December 6-10
, 
2016
. 
In: 
Cancer Res
2017
;
77
 (
4 Suppl.
)
, Abstract No. 
P6-11-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Gallagher RI, Yau C, Wolf DM, et al.
Quantitative ERα measurements in TNBC from the I-SPY 2 TRIAL correlate with HER2-EGFR co-activation and heterodimerization
.
2016 San Antonio Breast Cancer Symposium
, 
December 6-10
, 
2016
. 
In: 
Cancer Res
2016
;
77
 (
4 Suppl.
)
, Abstract No. 
P3-05-02
.
abstract
doi link
poster (pdf)
slides (pdf)
Wolf DM, Yau C, Sanil A, et al.
DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer
.
2016 San Antonio Breast Cancer Symposium
, 
December 6-10
, 
2016
. 
In: 
Cancer Res
2016
;
77
 (
4 Suppl.
)
, Abstract No. 
S2-06
.
abstract
doi link
poster (pdf)
slides (pdf)
-- view older abstracts --

The I-SPY Trials

Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.

 
Quick Links:
Media CenterCareersInvestigator Login
© 2019  Quantum Leap Healthcare Collaborative